These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Use of granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with hydroxyurea as post-transplant therapy in chronic myelogenous leukemia patients autografted with unmanipulated hematopoietic cells. Carlo-Stella C; Regazzi E; Andrizzi C; Savoldo B; Garau D; Montefusco E; Vignetti M; Mandelli F; Rizzoli V; Meloni G Haematologica; 1997; 82(3):291-6. PubMed ID: 9234574 [TBL] [Abstract][Full Text] [Related]
3. Collection of Philadelphia-negative stem cells using recombinant human granulocyte colony-stimulating factor in chronic myeloid leukemia patients treated with alpha-interferon. Hernández-Boluda JC; Carreras E; Cervantes F; Marín P; Arellano-Rodrigo E; Rovira M; Solé F; Lloveras E; Espinet B; Ocejo A; Montserrat E Haematologica; 2002 Jan; 87(1):17-22. PubMed ID: 11801461 [TBL] [Abstract][Full Text] [Related]
4. High-dose chemo-radiotherapy followed by autologous Philadelphia chromosome-negative blood progenitor cell transplantation in patients with chronic myelogenous leukemia. Carella AM; Chimirri F; Podestà M; Pitto A; Piaggio G; Dejana A; Lerma E; Pollicardo N; Vassallo F; Soracco M; Benvenuto F; Valbonesi M; Carlier P; Vimercati R; Prencipe E; Gatti AM; Ferrara RA; Incagliato M; Florio G; Frassoni F Bone Marrow Transplant; 1996 Feb; 17(2):201-5. PubMed ID: 8640167 [TBL] [Abstract][Full Text] [Related]
5. Autologous transplantation with Philadelphia-negative progenitor cells for patients with chronic myeloid leukaemia (CML) failing to attain a cytogenetic response to alpha interferon. McBride NC; Cavenagh JD; Newland AC; Lillington DM; Murrell C; Kelsey SM Bone Marrow Transplant; 2000 Dec; 26(11):1165-72. PubMed ID: 11149726 [TBL] [Abstract][Full Text] [Related]
6. Collection of 'normal' blood repopulating cells during early hemopoietic recovery after intensive conventional chemotherapy in chronic myelogenous leukemia. Carella AM; Podesta M; Frassoni F; Raffo MR; Pollicardo N; Pungolino E; Vimercati R; Sessarego M; Parodi C; Rabitti C Bone Marrow Transplant; 1993 Sep; 12(3):267-71. PubMed ID: 7694724 [TBL] [Abstract][Full Text] [Related]
7. Collection of Ph-negative progenitor cells from interferon responsive patients with chronic myeloid leukemia: effect of granulocyte-colony-stimulating factor mobilization. Olavarria E; Parker S; Craddock C; Philpott N; Tiniakou M; Chase A; Kanfer E; Apperley JF; Goldman JM Haematologica; 2000 Jun; 85(6):647-52. PubMed ID: 10870123 [TBL] [Abstract][Full Text] [Related]
8. Collection of peripheral blood stem cells after a preceding autograft: unfavorable effect of prior interferon-alpha therapy. Singhal S; Mehta J; Desikan K; Siegel D; Singh J; Munshi N; Spoon D; Anaissie E; Ayers D; Barlogie B Bone Marrow Transplant; 1999 Jul; 24(1):13-7. PubMed ID: 10435728 [TBL] [Abstract][Full Text] [Related]
9. Molecular status of individual CFU-GM colonies derived from chemotherapy-mobilised peripheral blood stem cells in chronic myeloid leukaemia. Broughton CM; Sherrington P; Pender NT; Clark RE Genes Chromosomes Cancer; 1997 Apr; 18(4):292-8. PubMed ID: 9087569 [TBL] [Abstract][Full Text] [Related]
10. Mobilization of peripheral stem cells with intensive chemotherapy (ICE regimen) and G-CSF in chronic myeloid leukemia. Boqué C; Petit J; Sarrá J; Cancelas JA; Muñoz J; Español JI; de la Banda E; Aventin A; Berlanga J; Ferrá C; Amill B; Torrico C; Azqueta C; Llucià M; García J; Grañena A Bone Marrow Transplant; 1996 Nov; 18(5):879-84. PubMed ID: 8932840 [TBL] [Abstract][Full Text] [Related]
11. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim. Weaver CH; Schulman KA; Buckner CD Bone Marrow Transplant; 2001 May; 27 Suppl 2():S23-9. PubMed ID: 11436117 [TBL] [Abstract][Full Text] [Related]
12. Preliminary results of stem cell mobilization in chronic myeloid leukemia with a moderate intensity chemotherapy regimen and G-CSF or G-CSF plus IL-3. Aulitzky WE; Neubauer A; Kolbe K; Schneller F; Busemann C; Schleiermacher E; Peschel C; Siegert W; Huber C; Huhn D Bone Marrow Transplant; 1996 May; 17 Suppl 3():S67-9. PubMed ID: 8769707 [TBL] [Abstract][Full Text] [Related]
13. Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study. Lemoli RM; Visani G; Leopardi G; Motta MR; Rizzi S; Testoni N; Curti A; Tura S Bone Marrow Transplant; 1999 Feb; 23(3):235-41. PubMed ID: 10084254 [TBL] [Abstract][Full Text] [Related]
14. Mobilisation of haemopoietic progenitors in CML: a second course of intensive chemotherapy does not improve Ph-negativity in stem cell harvests. Janssen JJ; van Rijn RS; van der Holt B; Schuurhuis GJ; Vellenga E; Verhoef GE; Ossenkoppele GJ; van den Berg E; Hagemeijer A; Släter R; Nieuwint AW; Cornelissen JJ Bone Marrow Transplant; 2000 Jun; 25(11):1147-55. PubMed ID: 10849527 [TBL] [Abstract][Full Text] [Related]
15. Recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells. Hohaus S; Martin H; Wassmann B; Egerer G; Haus U; Färber L; Burger KJ; Goldschmidt H; Hoelzer D; Haas R Bone Marrow Transplant; 1998 Oct; 22(7):625-30. PubMed ID: 9818688 [TBL] [Abstract][Full Text] [Related]
16. Mini-ICE regimen as mobilization therapy for chronic myelogenous leukaemia patients at diagnosis. Sureda A; Petit J; Brunet S; Boqué C; Aventín A; Martino R; González JR; Amill B; Larriba I; Blanco A; Martín-Henao GA; Sierra J; Grañena A Bone Marrow Transplant; 1999 Dec; 24(12):1285-90. PubMed ID: 10627636 [TBL] [Abstract][Full Text] [Related]
17. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma. Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493 [TBL] [Abstract][Full Text] [Related]
18. Chemotherapy for mobilisation of Ph-negative progenitor cells from patients with CML: impact of different mobilisation regimens. Deininger M; Pönisch W; Krahl R; Leiblein S; Edel E; Lange T; Fiedler F; Freund M; Franke A; Pasold R; von Grünhagen U; Herold M; Dölken G; Hoffmann FA; Uhle R; Schultze W; Steglich J; Schwarzer A; Richter P; Winkelmann C; Kettner E; Dachselt K; Subert R; Schwalbe E; Doepper J; Helbig W; Niederwieser D; Bone Marrow Transplant; 2001 Jun; 27(11):1125-32. PubMed ID: 11551022 [TBL] [Abstract][Full Text] [Related]
19. Treatment of chronic myelogenous leukemia with autologous bone marrow transplantation followed by roquinimex. Rowe JM; Rapoport AP; Ryan DH; Nilsson BI; Duerst RE; Packman CH; Abboud CN; DiPersio JF; Linder T; Wang N; Simonsson B; Liesveld JL Bone Marrow Transplant; 1999 Nov; 24(10):1057-63. PubMed ID: 10578155 [TBL] [Abstract][Full Text] [Related]
20. Selective overshoot of Ph-negative blood hemopoietic cells after intensive idarubicin-containing regimen and their repopulating capacity after reinfusion. Carella AM; Podestà M; Frassoni F; Pungolino E; Pollicardo N; Raffo MR; Ferrero R; Benvenuto F; Figari O; Giordano D Stem Cells; 1993 Oct; 11 Suppl 3():67-72. PubMed ID: 7905325 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]